Dong-A ST Co Ltd (Dong-A ST) is a pharmaceutical company that produces and distributes ethical drugs, medical devices, and diagnostic tests in South Korea. The company's range of ethical drugs includes gonadopin injection, dulastin progression-free survival, mainta injection, monotaxel injection, motilitone tablet, suganon tablet, sugamet XR tablet, closerin capsule, growtropin II, and leucostim. Additionally, Dong-A ST provides diagnostic solutions for detecting diseases such as Malaria, dengue combo, anti-HBs, HBsAg, Hepatitis C, HIV 1/2, Syphilis, and Ebola Ag. The company is also engaged in research for the development of new drugs.

Novel Drug Development: Dong-A ST is focused on developing novel drugs, particularly in the areas of oncology, immunology, and neurodegenerative diseases. The company has a strong pipeline of promising drug candidates. Biologics: Dong-A ST is actively involved in the development of biologics, including monoclonal antibodies and recombinant proteins. Platform Technologies: The company is leveraging platform technologies such as PROTAC to develop novel therapeutics. Open Innovation: Dong-A ST collaborates with academic institutions, research organizations, and other pharmaceutical companies to accelerate drug development. Global R&D Network: The company has established a global R&D network to facilitate access to cutting-edge technologies and talent.

Public

Pharma, Bio